#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dementia Alzheimer's type Dermatitis atopic Asthma Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Glycogen storage disease type V Pericarditis Endometrial adenocarcinoma Haemophagocytic lymphohistiocytosis Rectal cancer Leukocyte adhesion deficiency type I Oesophageal adenocarcinoma Synovial sarcoma metastatic Necrotising enterocolitis neonatal Wolfram syndrome Dedifferentiated liposarcoma Myotonic dystrophy Raynaud's phenomenon Acute myeloid leukaemia (in remission) Chronic myeloid leukaemia More trials…

    Learn about Rare Diseases

    Antithrombin III deficiency – Trials in Disease Alagille syndrome – Treatment Small intestine leiomyosarcoma – Diagnostics Wolfram syndrome – Diagnostics Mitochondrial myopathy – Life with Disease Wiskott-Aldrich syndrome – Treatment Von Willebrand’s disease – Basic Information Bronchiolitis obliterans syndrome – Basic Information Waldenstrom’s macroglobulinaemia refractory Haemolytic uraemic syndrome – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    F770/05 Acenocoumarol Ataluren Ligelizumab Mebendazole Sar442970 Iptacopan Hepatitis B Surface Antigen Sotalol Latanoprost Cetrimide Fluoxetine Dimethyl Fumarate Gen1046 Paroxetine Hydrochloride Nazartinib Letrozole Rineterkib Tofacitinib Pelacarsen More therapies…

    Learn about Your Condition

    Myocarditis Milk allergy Anaemia of chronic disease Renal disorder Alveolar rhabdomyosarcoma Metabolic disorder Muscle strain Macular oedema Multifocal motor neuropathy Partial lipodystrophy Thrombolysis Cardiac failure chronic Alopecia areata Craniocerebral injury Overweight More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Institut Paoli-Calmettes Cancer Centre

Institut Paoli-Calmettes Cancer Centre

2bj Balcqsnpz Dy Shlcbs Mewyyshagst Bv 1riz Maqzcfoymd 1jjsqo Fxugua

Want to learn more about this study or check if you can participate? Contact us.

  • Study Comparing Pralsetinib and Standard Drug Combination for Patients with Advanced RET Fusion-Positive Non-Small Cell Lung Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Lung neoplasm malignant
    • Non-small cell lung cancer
    Investigated Drugs:
    • Pralsetinib
    • Carboplatin
    • Cisplatin
    Belgium France Germany Ireland Italy The Netherlands +4

  • Study on the Safety and Effectiveness of Epcoritamab with R-CHOP for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Epcoritamab
    • Cyclophosphamide
    • Doxorubicin Hydrochloride
    Austria Belgium Bulgaria Croatia Czechia Denmark +10

  • Study of Pembrolizumab, Vibostolimab, and Belzutifan for Patients with Metastatic Castration-Resistant Prostate Cancer

    Not recruiting

    1 1 1 1
    Investigated Diseases:
    • Prostate cancer
    Investigated Drugs:
    • Vibostolimab
    • Abiraterone
    • Belzutifan
    Austria Denmark Finland France Germany Ireland +5

  • Study of Niraparib and Dostarlimab Combined with Platinum Therapy for Newly Diagnosed Stage III or IV Non-mucinous Epithelial Ovarian Cancer

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Dostarlimab
    • Niraparib Tosilate Monohydrate
    Belgium Czechia Denmark Finland France Germany +7

  • Durvalumab Maintenance Therapy for Frail Patients with Limited Stage Small Cell Lung Cancer After Chemoradiotherapy

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Durvalumab
    France

  • Study of Datopotamab Deruxtecan and Pembrolizumab for Patients with Advanced or Metastatic Non-small Cell Lung Cancer Without Actionable Genomic Alterations

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Datopotamab Deruxtecan
    • Pembrolizumab
    Austria Belgium France Germany Greece Hungary +6

  • Study on the Safety and Effectiveness of Vepdegestrant and PF-07220060 for Adults with ER+/HER2- Advanced or Metastatic Breast Cancer

    Not recruiting

    1 1 1
    Investigated Diseases:
    • Breast cancer
    Investigated Drugs:
    • Pf-07220060 Monohydrate
    • (3S)-3-[6-[4-[[1-[4-[(1R,2S)-6-Hydroxy-2-Phenyl-1,2,3,4-Tetrahydronaphthalen-1-Yl]Phenyl]Piperidin-4-Yl]Methyl]Piperazin-1-Yl]-3-Oxo-1H-Isoindol-2-Yl]Piperidine-2,6-Dione
    Belgium France Spain

  • Study on Mosunetuzumab and Lenalidomide for Patients with Untreated Follicular Lymphoma

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Bendamustine Hydrochloride
    • Cyclophosphamide
    • Doxorubicin Hydrochloride
    Austria Belgium France Germany Portugal Spain

  • Study on Ribociclib, Alpelisib, and Letrozole for Adults with Advanced Hormone Receptor-Positive Breast Cancer

    Not recruiting

    1 1 1 1
    Investigated Diseases:
    • Breast cancer
    Investigated Drugs:
    • Alpelisib
    • Letrozole
    • Ribociclib
    France Spain

  • Study of Lacutamab Alone or with Chemotherapy for Patients with Advanced T-Cell Lymphoma

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Cutaneous T-cell lymphoma recurrent
    • Cutaneous T-cell lymphoma
    Investigated Drugs:
    • Lacutamab
    Belgium France Germany Italy Poland Spain
Previous Page
1 … 31 32 33 34 35 … 42
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!